EW News and Press, Edwards Lifesciences Corporation From 10/30/22

Summary Edwards Lifesciences has seen shares cut nearly in half from the highs of last year. This is mostly in response to higher interest rates and an overreaction seen towards the upside last year. Current multiples remain demanding, but underlying strength remains solid. ...

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha , iTunes , Stitcher and Spotify . For further details see: Wall Street Breakfast: What Moved Markets

Stocks rallied on Friday, boosted by a strong earnings report from Apple. All the major averages rose more than 2%, with the Dow climbing more than 800 points to secure its sixth straight day of gains. While Apple gave a lift to the overall market, Amazon ( AMZN ) created a signific...

Summary The Health Care sector continues to generate alpha in 2022, but not all of its holdings are a source of relative safety. Edwards Lifesciences reported a poor Q3 and slashed guidance. Traders reacted harshly to the EPS miss. The stock still looks on the pricey side but ...

Shares of medical device maker Edwards Lifesciences (NYSE: EW) fell 16.6% through 11:45 a.m. ET on Friday even though the company missed analyst targets for third-quarter earnings last night by only the slimmest of margins. Analysts had forecast that Edwards would show earni...

Edwards Lifesciences Corp (EW) Q3 2022 Earnings Conference Call October 27, 2022, 17:00 ET Company Participants Mark Wilterding - VP, IR Michael Mussallem - Chairman & CEO Scott Ullem - Corporate VP & CFO Bernard Zovighian - Corporate VP, Transcathete...

Edwards Lifesciences ( NYSE: EW ) is down 11% in after-hours trading after the company's Q3 2022 top and bottom line results missed and its full-year adjusted EPS guidance range was amended to below the consensus estimate. Edwards ( EW ) now projects 2022 adjus...

Edwards Lifesciences press release ( NYSE: EW ): Q3 Non-GAAP EPS of $0.61 misses by $0.01 . Revenue of $1.32B (+0.8% Y/Y) misses by $10M . Q3 TAVR sales grew 1%; constant currency sales grew 6% Outlook: 2022 adjusted EPS guidance revised to the range of...

EDWARDS LIFESCIENCES REPORTS THIRD QUARTER RESULTS PR Newswire IRVINE, Calif. , Oct. 27, 2022 /PRNewswire/ -- Edwards Lifesciences (NYSE: EW) today reported financial results for the quarter ended September 30, 2022. Third Quarter...

Edwards Lifesciences ( NYSE: EW ) is scheduled to announce Q3 earnings results on Thursday, October 27th, after market close. The consensus EPS Estimate is $0.62 and the consensus Revenue Estimate is $1.33B (+1.5% Y/Y). Over the last 2 years, EW has beaten EPS estima...